Menotropin - Ferring

Drug Profile

Menotropin - Ferring

Alternative Names: HMG; HP-hMG; Human menopausal gonadotrophin; Menogon; Menopur; Menotrophin; Menotropins; Merapur; Meropur; Repronex

Latest Information Update: 20 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Infertility therapies; Menotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility; Polycystic ovary syndrome

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 20 Jul 2016 Launched for Female infertility in South Korea (SC) before July 2016
  • 12 Mar 2014 Ferring completes a phase III trial comparing 450 and 600IU daily doses of menotropin in Female infertility in Canada (NCT00971152)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top